ARTICLE | Discovery & Translation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey Part II
By C. Simone Fishburn, Editor in Chief
December 23, 2023 2:31 AM UTC
Improving on validated technologies trumps forging new ones when it comes to expectations for new modalities in the next few years. Despite the proliferation of modalities, from gene therapies and RNAs to different kinds of cell therapy, it is the next-gen formats of the antibody workhorse that will drive the greatest progress into the second half of this decade, according to investors and executives surveyed by BioCentury.
Though small molecules and traditional mAbs will remain core to drug development, the engine of innovation is clearly in high gear for creation and improvement of new modality therapeutics…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650994/taking-next-gen-mabs-to-new-heights-will-lead-modality-innovation